On the other hand: the company was charging $13/pill for a long time. Shkreli hikes it immensely, and only two months later a competitor starts selling it for $

On the other hand: the company was charging $13/pill for a long time. Shkreli hikes it immensely, and only two months later a competitor starts selling it for $1/pill: https://www.cnbc.com/2015/11/30/express-scripts-imprimis-to-offer-daraprim-alternative.html https://www.cnbc.com/2015/11/30/express-scripts-imprimis-to-... Arguably, Shkreli's actions incentivized competition (like the parent poster talked about), and at the cost of only two months of unaffordable prices, patients were left much better off. Personally I still find his action abhorrent, but the facts do have some weight.